Tenvie Therapeutics, a San Francisco, CA-based biotechnology firm dedicated to engineering small molecules for the therapy of neurological ailments, raised $200M in funding.
The spherical was led by ARCH Enterprise Companions, F-Prime Capital, Mubadala Capital, with participation from different buyers.
The corporate intends to make use of the funds to speed up its development and growth efforts.
Tenvie is a biotechnology firm dedicated to engineering small molecules that rework the therapy of neurological ailments. Its basis is purpose-built with a various portfolio of small molecules and a confirmed group of CNS drug builders to quickly ship a number of medical belongings. The corporate is advancing a pipeline of therapeutics targeted on treating neurological, cardiometabolic, and ophthalmic ailments. Its portfolio of wholly owned, extremely brain-penetrant, and precision-designed peripherally restricted small molecules handle three key drivers of illness: resolving irritation, rescuing metabolic dysfunction, and restoring lysosomal perform.
The corporate’s most superior applications goal NLRP3 and SARM1, with extra applications in preclinical growth
Its Board of Administrators contains:
- Tony Estrada, Ph.D., President, Chief Scientific Officer and Board Director
- Brian Cuneo, J.D., Chief Enterprise and Authorized Officer
- Tanya Fischer, M.D., Ph.D., Chief Medical Officer
- Paul L. Berns, Government Chair of Tenvie’s Board, Managing Director, ARCH Enterprise Companions
- Kristina Burow, Tenvie Board Director, Managing Director, ARCH Enterprise Companions
- Alaa Halawa, Tenvie Board Director, Head of Healthcare and Government Director, Mubadala Capital
- Joe Lewcock, Ph.D., Tenvie Board Director, Chief Scientific Officer, Denali Therapeutics
- Stacie Weninger, Ph.D., Tenvie Board Director, President, FBRI, Enterprise Associate, F-Prime Capital
FinSMEs
08/01/2025
